

BYDUREON Regulatory Update: Exenatide Thorough QT Study Design

- Thorough QT study per E14 guidance utilizing IV infusion to assess QTc at therapeutic and supratherapeutic concentrations of exenatide
- Protocol design incorporates FDA guidance and feedback
- Target plasma concentration: 300-500 picograms/mL
- Study length enables response to October 2010 BYDUREON complete response letter in 2H 2011

